Navigation Links
TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S, Copenhagen, Denmark
Date:5/9/2013

SAN DIEGO, May 9, 2013 /PRNewswire/ -- TriLink BioTechnologies, Inc. (TriLink, www.trilinkbiotech.com), a leader in manufacturing high quality oligonucleotides, nucleoside triphosphates and mRNA, announced that it has signed a licensing agreement with QuantiBact A/S (QuantiBact, www.quantibact.com) to offer twisted intercalating nucleic acid (TINA) modified oligos.

TINA molecules are intercalators placed at the 5' end of primers to stabilize duplex formation. Their unique properties improve the sensitivity and specificity of endpoint and real-time PCR. TINA may find applications wherever an enhanced Tm is required such as triplex formation or potentially even gene silencing.

"At QuantiBact we strive to make our technologies available throughout the research and diagnostic communities. We appreciate being able to work with dedicated companies that hold high recognition in the market place. The market position as well as in depth knowledge of nucleic acids embedded within TriLink will enable us to further reach our goal," says Palle Schelde , CEO, Managing Director, QuantiBact.

"At TriLink we pride ourselves on our quality and our ability to handle unique nucleic acid modifications. This makes us an ideal manufacturer of TINA oligos," stated Richard Hogrefe , Ph.D., President and CEO of TriLink. "We are excited to work with the great folks at QuantiBact and see how this technology might advance molecular diagnostics."

TINA modified oligonucleotides will be available from TriLink in June, 2013. Visit www.trilinkbiotech.com/TINA for the most up-to date information.

About QuantiBact
QuantiBact develops novel generic nucleic acid tools for research and diagnostic use. The objective of the technology is to minimize turnaround time of diagnostic procedures, increased sensitivity and fidelity of quantification. Furthermore the technology enables complex PCR multiplexing as well as utilization of crude sample material. The generic nature of the technology allows application in a broad variety of research and diagnostic applications. QuantiBact was founded on the nucleic acid intercalator research carried out at University of Southern Denmark, Odense and Hvidovre Hospital, Copenhagen. For more information, visit their website at www.quantibact.com.

About TriLink
TriLink manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp™ PCR products for the diagnostic and OEM markets. In addition, custom chemistry, long RNA transcript synthesis and contract research services and ISO/QSR compliant cGMP production facilities are offered. TriLink's solutions help advance drug discovery and biomedical research. Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 50 scientists and other professionals. For more information about the firm and products, visit our web site at www.trilinkbiotech.com.

Angela Tenenini Asuncion , MBA
marketing@trilinkbiotech.com


'/>"/>
SOURCE TriLink BioTechnologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. TriLink BioTechnologies Awards Keck Science Department ResearchReward
2. Leading Scientists to Debate Views on Rejuvenation Biotechnologies
3. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
4. Medical Marijuana, Inc. Portfolio Company CanChew BioTechnologies Inc. Updates and Expands Free Product Trial
5. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
6. OPX Biotechnologies Selected as Innovation Pioneer at IHS CERAWeek
7. Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
10. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
11. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... - BioAmber Inc. (NYSE: BIOA ), a leader ... & Co. Ltd., its partner in the ... an additional CDN$25 million in the joint venture for ... to 40%.  Mitsui will also play a stronger role ... Sarnia , providing dedicated resources alongside BioAmber,s ...
(Date:2/10/2016)... , February 10, 2016 Early-career researchers ... , Peru , Uganda and ... life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are being ... and epidemiology. They are also celebrated for mentoring young women scientists who ...
(Date:2/10/2016)... , Feb. 10, 2016  The Maryland House ... , has announced that University of Maryland School of ... MBA and University of Maryland Medical System President and ... the "Speaker,s Medallion," the highest honor given to the ... Delegates. Dean Reece and Mr. Chrencik ...
(Date:2/10/2016)... Feb. 10, 2016 NX Prenatal Inc., a ... NeXosome® technology for early warning of adverse pregnancy ... recent study by Dr. Thomas McElrath ... Maternal Fetal Medicine,s (SMFM) annual meeting held in ... , 2016.  The presentation reported initial positive top-line ...
Breaking Biology Technology:
(Date:2/10/2016)... February 10, 2016 ... to 2016 iris recognition market report, combined ... is more widely accepted for border control. ... fingerprint and iris recognition technology in a ... avoid purchasing two individual biometrics devices. ...
(Date:2/9/2016)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2015.  ... 2015 was $6.9 million, an increase of 61% compared to $4.3 ... fourth quarter of 2015 was $2.6 million compared to $0.2 million ... --> Higher revenue and operating income in the ...
(Date:2/9/2016)... 9, 2016 Vigilant Solutions announces today that an ... to develop a lead in a difficult homicide case. The ... to locate the suspect vehicle. Due to the ongoing investigation, ... been omitted at the agency,s request. --> ... "Our victim was found deceased at an intersection here in ...
Breaking Biology News(10 mins):